CINCINNATI –
March 20, 2008 – General Data Company, Inc. has entered into a Supply and
Distribution Agreement with Dako, a global provider of solutions for
tissue-based cancer diagnostics, that makes Dako the exclusive supplier of
General Data's ID/Positive lab specimen identification and tracking products
outside of the United States.
Over the last 27 years, General Data has established itself
as a leader in bar code-based identification, tracking and error-proofing
systems for healthcare. General Data’s ID/Positive system, which can be
integrated with a hospital’s existing laboratory information system, allows
lab technicians to use bar code technology to identify and track tissue
specimens through the lab, reducing manual transcription errors and
streamlining laboratory processes. General Data has provided its ID/Positive
system to a number of hospitals throughout the US, including Massachusetts
General Hospital in Boston, Massachusetts and TriCore Reference Laboratories
in Albuquerque, New Mexico.
The FDA estimates that the use of bar code identification
and data management systems in healthcare can reduce errors by more than 80
percent, and will save providers more than $83 billion over the next 20
years.
“Patient safety is a challenge to every hospital and
healthcare system. Keeping track of the patient’s identity through all
laboratory processes is a critical step forward. We believe General Data to
have the strongest product portfolio in the area of True Positive ID, and
that it optimally complements Dako’s portfolio of know-how, instruments,
reagents and software solutions for cancer diagnostics. We see this, when
considered in combination with our global distribution reach, as a very
fruitful partnership,” says Patrik Dahlén, CEO and President of the Dako
Group.
Dako’s system of distribution will allow General Data to
deliver its quality products to healthcare providers in a more efficient way
and on a global scale, thereby reducing life-threatening errors and
increasing patient safety for health systems throughout the world. Dako’s
distribution rights for General Data’s products cover all healthcare markets
globally – and Dako becomes exclusive supplier outside the US.
”General Data is proud to partner with Dako to bring
innovative bar code technologies to the lab for effective, reliable
identification and tracking of tissue samples,” says Pete Wenzel, CEO and
President of General Data. “Integration of our ID/Positive and StainerShield
product solutions with the Dako Link product, Dako’s global customer base
and drive for quality is a perfect fit. Our focus is on helping healthcare
providers deliver higher levels of patient safety and care, and our
partnership with Dako will speed that process on a global basis.”
For more information about General Data Company, Inc.,
contact Ralph Moher at (513) 752-7978 ext. 2219 or moher@general-data.com.
About General Data Company Inc.
General Data Company, Inc. is recognized as a premiere provider of
innovative bar code identification and automated data collection products
and solutions that enable organizations to streamline workflow, error proof
processes, better manage critical data, and improve business-process
accuracy, productivity and performance. Founded in 1981, General Data is a
privately held company with headquarters in Cincinnati, Ohio USA. More
information on General Data’s products and solutions can be found at
www.general-data.com.
About Dako
Dako (www.dako.com) is a
global leader in tissue-based cancer diagnostics. Hospital and research
laboratories worldwide use Dako’s know-how, reagents, instruments and
software to make precise diagnoses and determine the most effective
treatment for patients suffering from cancer. Employing more than 1,000
people and operating in more than 70 countries, Dako covers essentially all
of the global anatomic pathology markets. Dako, based in Denmark, is owned
by a private equity fund, EQT.
# # # |
